Merck Presents Phase II Data On Chronic Cough Candidate
Zacks Investment Research | May 23, 2017 05:21AM ET
Merck (NYSE:MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference. The study was designed to evaluate the safety, efficacy and therapeutic dose range of MK-7264 for the treatment of chronic cough.
Data from the study revealed that the highest dose of 50 mg, given twice daily, resulted in reduction of Awake Cough Frequency (coughs/hour), the primary endpoint, by 37% from baseline compared to placebo after 12 weeks of treatment. The 50 mg dose also demonstrated a reduction in patient-reported cough severity. However, lower doses (7.5 mg and 20 mg) were not statistically significant.
The company plans a discussion with regulatory agencies for initiating phase III clinical development of MK-7264 by the end of 2017.
Shares of Merck have outperformed the Zacks-classified Large Cap Pharma industry in the last year. The stock has gained 15.2% during the period, while the broader industry witnessed an increase of 4.3%.
We remind the investors that MK-7264 is also being evaluated in a phase II study for idiopathic pulmonary fibrosis (IPF) with cough. Results from the study, presented at the ATS International Conference last year, showed that MK-7264 significantly reduced cough frequency, otably, MK-7264 was added to Merck’s portfolio following acquisition of the biotech company Afferent Pharmaceuticals in Jul 2016.
According to information provided in the company’s press release, chronic cough is estimated to affect about 10% of adults in the U.S. With no approved therapies for its treatment, there is significant unmet need in this area.
We note that Merck has made significant progress with its pipeline and is working on bringing new products to the market. The company has over 10 candidates (including Keytruda) which are in advanced stages of development. It has prioritized its pipeline so that the candidates with highest potential can get the required support.
Zacks Rank & Key Picks
Merck currently carries a Zacks Rank #2 (Buy). Other top-placed stocks in the healthcare sector include VIVUS, Inc. (NASDAQ:VVUS) , Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Bayer (DE:BAYGN) AG (OTC:BAYRY) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see .
Get The News You Want
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 30 days. The company posted positive earnings surprises in all four trailing quarters with an average beat of 233.69%.
Regeneron’s earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, over last 30 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.
Bayer’s earnings per share estimates increased from $8.19 to $8.75, over the last 30 days for 2017. The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 10.25%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.